Your browser is no longer supported. Please, upgrade your browser.
HomeNewsScreenerMapsGroupsPortfolioInsiderFuturesForexBacktestsElite Help
publish chart | save to portfolio | create alert Type: candle | line | advanced | interactive | perf    Timeframe: intraday | daily | weekly | monthly  Settings
AMGN Amgen Inc. daily Stock Chart
AMGN [NASD]
Amgen Inc.
Healthcare | Biotechnology | USA
financial highlights | statements
IndexS&P 500 P/E15.46 EPS (ttm)11.00 Insider Own0.20% Shs Outstand734.00M Perf Week-2.10%
Market Cap124.81B Forward P/E13.27 EPS next Y12.81 Insider Trans-0.45% Shs Float728.63M Perf Month-4.15%
Income8.17B PEG3.60 EPS next Q3.11 Inst Own81.10% Short Float1.07% Perf Quarter6.28%
Sales23.05B P/S5.41 EPS this Y13.10% Inst Trans-0.33% Short Ratio2.45 Perf Half Y1.18%
Book/sh43.22 P/B3.93 EPS next Y1.93% ROA10.40% Target Price187.21 Perf Year-2.60%
Cash/sh53.44 P/C3.18 EPS next 5Y4.29% ROE26.60% 52W Range133.64 - 184.21 Perf YTD16.30%
Dividend4.60 P/FCF17.13 EPS past 5Y20.50% ROI13.00% 52W High-6.61% Beta1.36
Dividend %2.71% Quick Ratio5.80 Sales past 5Y8.10% Gross Margin82.20% 52W Low28.74% ATR2.37
Employees19200 Current Ratio6.20 Sales Q/Q2.10% Oper. Margin44.70% RSI (14)48.60 Volatility1.33% 1.31%
OptionableYes Debt/Eq1.11 EPS Q/Q17.80% Profit Margin35.50% Rel Volume0.40 Prev Close170.04
ShortableYes LT Debt/Eq1.06 EarningsJul 25 AMC Payout38.80% Avg Volume3.19M Price172.04
Recom2.40 SMA20-1.59% SMA500.10% SMA2006.39% Volume742,499 Change1.18%
Jul-11-17Resumed Jefferies Buy
Jun-23-17Initiated Deutsche Bank Hold $172
Apr-05-17Downgrade Jefferies Buy → Hold
Mar-09-17Initiated UBS Neutral $185
Feb-01-17Upgrade BofA/Merrill Neutral → Buy
Dec-20-16Downgrade Credit Suisse Outperform → Neutral
Dec-13-16Initiated Oppenheimer Outperform
Nov-08-16Initiated Mizuho Buy $164
Aug-26-16Initiated Gabelli & Co Hold
Jun-29-16Initiated Bernstein Mkt Perform
Feb-25-16Initiated Citigroup Neutral $165
Feb-08-16Reiterated Argus Buy $202 → $185
Jan-20-16Initiated Credit Suisse Outperform $205
Dec-15-15Upgrade Morgan Stanley Equal-Weight → Overweight
Dec-04-15Initiated Wells Fargo Market Perform
Oct-29-15Reiterated UBS Buy $168 → $180
Sep-01-15Initiated Raymond James Mkt Perform
Jul-31-15Reiterated RBC Capital Mkts Outperform $185 → $190
Jul-31-15Reiterated Deutsche Bank Buy $192 → $195
Jul-31-15Reiterated Barclays Equal Weight $180 → $185
Aug-16-17 10:36AM  What We May See from Amgens Vectibix in 2017 Market Realist
10:08AM  Biogen: Goldman Has Conviction! Barrons.com
09:07AM  How Amgens Neutropenia Drugs Are Positioned after 2Q17 Market Realist
07:36AM  What Amgen Expects from Blincyto in 2017 Market Realist
Aug-15-17 10:36AM  How Amgens Repatha Performed in 2Q17 Market Realist
10:09AM  Can Ligand's Captisol Deals Boost Growth in the Long Run? Zacks
09:07AM  Gauging Amgens Xgeva Contribution in 2017 Market Realist
09:05AM  Are Amgen's New Drugs Doing Well Enough to Drive Sales? Zacks
07:38AM  What Kyprolis Could Do for Amgens Revenue Growth Market Realist
Aug-14-17 04:36PM  Behind Amgens High Revenue Growth from Prolia in 2Q17 Market Realist
02:36PM  Inside Amgens 2Q17 Performance Market Realist
01:06PM  What Amgens Analysts Recommend in August 2017 Market Realist
11:43AM  The Zacks Analyst Blog Highlights: Disney, Amgen, Caterpillar, S&P Global and Emerson Electric Zacks
10:37AM  Pfizers Major Growth Drivers in 2Q17 Market Realist
07:40AM  Dividend Coverage: This Biotech Drugmaker Pays Higher Dividend than the Healthcare Sector by Over 316%; Will Trade Ex-Dividend on August 15, 2017 ACCESSWIRE
Aug-12-17 09:50PM  Edited Transcript of AMGN earnings conference call or presentation 25-Jul-17 9:00pm GMT Thomson Reuters StreetEvents
08:00AM  See what the IHS Markit Score report has to say about Amgen Inc. Markit
Aug-11-17 05:04PM  Top Analyst Reports for Disney, Amgen & Caterpillar Zacks
04:52PM  ETFs with exposure to Amgen, Inc. : August 11, 2017 Capital Cube
10:19AM  Amgen, Inc. breached its 50 day moving average in a Bearish Manner : AMGN-US : August 11, 2017 Capital Cube
08:00AM  IHS Markit Score Update: Drop in demand for ETFs holding Amgen Inc is a negative sign for its shares Markit
Aug-10-17 09:07AM  Celgenes Otezla Witnessed High Revenue Growth in 2Q17 Market Realist
08:50AM  Major Biotechs Send Short Sellers Running for Cover 24/7 Wall St.
08:00AM  See what the IHS Markit Score report has to say about Amgen Inc. Markit
07:38AM  Trade of the Day: Amgen, Inc. (AMGN) Stock Is a Quiet Bull InvestorPlace
Aug-09-17 01:02PM  Analysts Recommendations for Celgene in August 2017 Market Realist
08:00AM  See what the IHS Markit Score report has to say about Amgen Inc. Markit
Aug-08-17 11:31AM  Valeant Pops on Earnings Beat, Debt Reduction Effort TheStreet.com
11:14AM  Ligand (LGND) Q2 Earnings & Revenues Top, 2017 View Raised Zacks
09:31AM  Amgen Remains A Standout Among Biotechs Forbes
02:00AM  Scottish Medicines Consortium Accepts Amgen's Multiple Myeloma Treatment, KYPROLIS® (carfilzomib), in Combination with Dexamethasone, for use at First Relapse PR Newswire
Aug-07-17 04:19PM  Here's Why Array BioPharma Inc. Fell 13.7% in July Motley Fool
09:08AM  Why A Tax Holiday Alone Won't Spark Biotech M&A Barrons.com
Aug-05-17 11:52AM  Earnings Preview: What To Expect From Valeant Pharmaceuticals On Tuesday Forbes
Aug-03-17 04:23PM  The Surprising Reason Regeneron Toppled Despite Its Beat-And-Raise Investor's Business Daily
Aug-02-17 11:01AM  Earnings Preview: What To Expect From Teva Pharmaceutical On Thursday Forbes
08:32AM  Biotech Stock Roundup: Q2 Earnings from Gilead, CELG & More, Dynavax Up on Panel Vote Zacks
Aug-01-17 12:26AM  3 ETFs to Watch Out for on Biotech Earnings Zacks
Jul-31-17 04:46PM  Express Scripts to cover Mylan's EpiPen, exclude rivals Reuters
09:10AM  Amgen Submits Supplemental Biologics License Application For Prolia® (denosumab) In Glucocorticoid-Induced Osteoporosis PR Newswire
09:00AM  Amgen And Allergan Submit Biosimilar Biologics License Application For ABP 980 To US Food And Drug Administration PR Newswire
Jul-30-17 03:20PM  Court Ruling on 'Biosimilars' Sets Stage for More Drug Acquisitions TheStreet.com
Jul-28-17 04:01PM  Amgen Announces 2017 Third Quarter Dividend PR Newswire
12:37PM  Amgen, Inc. :AMGN-US: Earnings Analysis: Q2, 2017 By the Numbers : July 28, 2017 Capital Cube
Jul-27-17 06:19PM  Amgen gets fast U.S. FDA review for adding heart benefits to cholesterol drug label Reuters
05:49PM  FDA Grants Priority Review For Amgen's Supplemental Biologics License Application For Repatha® (evolocumab) To Include Data On Reducing Risk Of Cardiovascular Events PR Newswire
10:44AM  Company News for July 27, 2017 Zacks
08:00AM  Today's Research Reports on Stocks to Watch: Amgen and United States Steel Corporation ACCESSWIRE
01:07AM  Asian shares gain on strong earnings, dovish Fed policy Associated Press
Jul-26-17 04:33PM  'Poor Quality' Amgen Earnings Beat Doesn't Impress These Two Wall Street Analysts Benzinga
02:47PM  Amgen: It's Never Just About the Earnings Barrons.com
01:52PM  Amgen turned in a strong second quarter but analysts say things are looking bleak MarketWatch
12:51PM  US STOCKS-Strong earnings power Wall St to record; Fed awaited Reuters
11:31AM  US STOCKS-Boeing, AT&T power Wall St to record; Fed in focus Reuters
11:02AM  Amgen shares drop as earnings report reveals embarrassingly bare drug pipeline CNBC
10:09AM  Amgen, Inc. (AMGN) Stock Is a Trade for Ailing Portfolios InvestorPlace
09:58AM  Amgen (AMGN) Stock Falls Despite Q2 Earnings & Sales Beat Zacks
09:35AM  Short Sellers Run for Cover From Major Biotech Stocks 24/7 Wall St.
08:30AM  2 Incredibly Cheap Dividend Stocks Motley Fool
08:15AM  Biotech Stock Roundup: Amgen, Biogen Top Q2 Estimates, Update on Incyte RA Drug Zacks
08:07AM  Early movers: KO, BA, F, DHI, HLT, ANTM, NOC, T, APRN, AMGN & more CNBC
Jul-25-17 09:52PM  Evening Movers: Chipotle Gains, Amgen Falls, US Steel Soars Barrons.com
09:24PM  Amgen beats Street 2Q forecasts Associated Press
05:30PM  Biotech still has more room to run: Technician CNBC Videos
05:02PM  Amgen Topples After Increased Forecast Still Lags Some Views Investor's Business Daily
04:27PM  Amgen shares down 3% after company's guidance on lower end of expectations MarketWatch
04:07PM  Amgen 2nd quarter profit tops Street estimates, raises forecast Reuters
04:07PM  Amgen beats on top line CNBC Videos
04:01PM  Amgen Reports Second Quarter 2017 Financial Results PR Newswire
Jul-24-17 05:24PM  Shrinking dollar could boost the market and make these stocks big winners CNBC
11:51AM  2 Ways To Trade This Week's Healthcare Earnings Benzinga
10:11AM  Surprise in Store for Healthcare in Q2: Buy Top-Ranked ETFs Zacks
08:16AM  Big Pharma Q2 Earnings Releases on Jul 25: LLY, BIIB, AMGN Zacks
Jul-23-17 04:19PM  Five Unappreciated Stocks With High Return On Invested Capital Forbes
11:50AM  3 Stocks That Are Absurdly Cheap Right Now Motley Fool
Jul-21-17 07:40PM  [$$] Clinical Development News, July 17-21 The Wall Street Journal
04:09PM  FDA Accepts Amgen's Biologics License Application for Aimovig GuruFocus.com
01:38PM  Will Gilead Beat 2Q Earnings? PerhapsBut Does It Matter? Barrons.com
08:48AM  Amgen (AMGN) to Report Q2 Earnings: What's in the Cards? Zacks
07:15AM  3 Dividend Stocks That Thrive in Market Crashes Motley Fool
Jul-20-17 04:30PM  FDA Accepts Biologics License Application For Aimovig (erenumab) PR Newswire
04:00PM  Amgen Announces Webcast of 2017 Second Quarter Financial Results PR Newswire
Jul-19-17 02:30PM  Biotech Stocks On Verge Of Next Major Move Up Investopedia
08:39AM  Biotech Stock Roundup: Vertex Boosted by CF Data, FDA Nod for Gilead, Puma Drugs Zacks
08:04AM  3 Dividend Stocks That Thrive in Both Bull and Bear Markets Motley Fool
07:33AM  Poor test results for Roche cloud growth prospects Reuters
Jul-18-17 02:27PM  Which Biotech Earnings Will Outperform? Barrons.com
12:03PM  Colorado biotech makes deal with industry giant American City Business Journals
10:37AM  Ligand Signs Agreement with Amgen, Grants Rights to Captisol Zacks
08:00AM  Amgen And Array BioPharma Announce Preclinical License And Collaboration Agreement In Inflammation PR Newswire
07:20AM  Featured Company News Amgen Submits Regulatory Applications in US, Europe to Include Overall Survival Data in KYPROLIS Label Accesswire
Jul-17-17 10:46AM  Amgen FDA Letter Isn't A Surprise (Or A Concern), Says Jefferies Barrons.com
10:29AM  Amgen (AMGN) Gets CRL for Osteoporosis Drug Evenity's BLA Zacks
Jul-16-17 06:00PM  Amgen And UCB Provide Update On Regulatory Status Of EVENITY (romosozumab) In The US PR Newswire
Jul-14-17 03:46PM  Amgen Applies to Have Kyprolis' Label Updated GuruFocus.com
09:00AM  Amgen Submits Regulatory Applications In US And Europe To Include Overall Survival Data In KYPROLIS® (Carfilzomib) Label PR Newswire
07:34AM  Trade of the Day: Amgen, Inc. (AMGN) Stock Is a Standout InvestorPlace
12:43AM  These 6 Big-Cap Stocks Are Within 1% Of Buy Points Investor's Business Daily
Jul-13-17 10:30AM  Amgen's Myeloma Drug Improves Overall Survival in Phase III Zacks
09:40AM  Short Sellers Hike Bets in Major Biotechs 24/7 Wall St.
Amgen Inc. discovers, develops, manufactures, and delivers human therapeutics worldwide. It offers products for the treatment of illness in the areas of oncology/hematology, cardiovascular, inflammation, bone health, nephrology, and neuroscience. The company's products include Evenity to treat osteoporosis in postmenopausal women; Prolia to treat postmenopausal women with osteoporosis; Xgeva for skeletal-related events prevention; Repatha to treat coronary artery diseases; Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Parsabiv to treat secondary hyperparathyroidism (sHPT); and Erenumab for the prevention of migraine. Its products also comprise Blincyto to treat patients with Philadelphia chromosome-negative relapsed or refractory B-cell precursor acute lymphoblastic leukemia; Kyprolis, a proteasome inhibitor for the treatment of multiple myeloma and small-cell lung cancer; Nplate, a thrombopoietic compound; AMJEVITA to treat psoriatic arthritis and polyarticular juvenile idiopathic arthritis, as well as ankylosing spondylitis and rheumatoid arthritis; ABP 215 for biosimilar candidates; and ABP 980 to treat human epidermal growth factor receptor 2-positive early breast cancer. The company's other marketed products include Neulasta, a pegylated protein to treat cancer patients; Aranesp to treat anemia; Sensipar/Mimpara products to treat sHPT in chronic kidney disease; EPOGEN to treat a lower-than-normal number of red blood cells; NEUPOGEN, a recombinant-methionyl human granulocyte colony-stimulating factor; and IMLYGIC to treat various cancer cells. It serves pharmaceutical wholesale distributors; and physicians or their clinics, dialysis centers, hospitals, and pharmacies, as well as consumers. The company has collaborative agreements with Pfizer Inc.; UCB; Bayer HealthCare Pharmaceuticals Inc.; Array BioPharma Inc.; and Syngene International Limited. Amgen Inc. was founded in 1980 and is headquartered in Thousand Oaks, California.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
BALTIMORE DAVIDDirectorMay 31Sale153.933,700569,54131,159Jun 02 07:21 PM
Patton Cynthia MSVP & CCOMay 24Sale154.402,922451,16421,292May 24 07:35 PM
de Carbonnel FrancoisDirectorSep 09Option Exercise71.645,000358,20021,171Sep 13 06:21 PM
open in yahoo | open in reuters | open in google